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Immune gene therapyAbstract The annual incidence of thyroid cancer worldwide is alarming. Despite current various
treatments such as surgical resection, radioiodine therapy and chemotherapy/radiotherapy, thyroid
carcinoma remains a lethal cancer. Assuredly, the operative and new treatment strategies are nec-
essary to control this malignancy. Gene therapy is regarded as one of the most reliable novel ther-
apeutic methods for hopeless cases of thyroid cancer and those who do not respond to the prevalent
treatments. Accumulated evidence suggests that interleukin-24 (IL-24), also known as melanoma
differentiation-associated gene-7, has very important roles in regulation of cell differentiation, cell
growth and apoptosis, and it is also a promising anticancer agent. Here, we propose that it could be
advantageous to evaluate the anti-tumoural effect of IL-24 in a mouse xenograft model of thyroid
cancer.
ª 2013 Tehran University of Medical Sciences. Published by Elsevier Ltd.
D license.Introduction
The thyroid is a main human endocrine gland that controls
heart rate, blood pressure, body temperature and metabolism[1]. Thyroid carcinoma is the most frequent endocrine malig-
nancy [2], and its incidence is more common than ovarian, uri-
nary bladder or pancreatic cancer, with an incidence 3 times
higher in women than in men [3].e-linked
damage;
98 241
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thyroid cancer have few therapeutic options, with a 30% re-
sponse rate to systemic chemotherapy and no proven survival
beneﬁt [4].
Papillary thyroid cancer (PTC) is the most common histo-
logical type of thyroid malignancy [5]. The genetic malfunc-
tions that cause thyroid neoplasia include rearrangements
and point mutations in some genes, such as RAS, RET and
p53. Specially, deﬁciency in DNA repair, apoptosis and tu-
mour suppressor gene malfunction result in thyroid tumours
[5].
Despite many traditional treatments for thyroid cancer,
including surgical resection, radioiodine therapy, thyrotropin
(thyroid stimulating hormone, TSH)-suppressive thyroxine
treatment and chemotherapy/radiotherapy, the chance of sur-
vival in patients is low. Thus, alternative approaches, such as
gene therapy, are of interest, and fortunately, thyroid tumours
are a good target, for two reasons. First, certain gene promot-
ers expressed in the thyroid tumours have no or very limited
expression elsewhere, and second, if the therapy leads to
destruction of all normal thyroid tissue, this would be inconse-
quential to destruction of the other tissues [5,6]. Gene therapy
can be effective and safe, but for each approach there is an
evaluation between the degree of effectiveness and undesirable
toxic effects that may occur due to non-selectivity. For exam-
ple, Nishihara et al. have reported the effect of Re-TG-tk/Cre-
loxP on FRTL-5, FRTC and FRO cell lines, which has extra-
thyroidal tissue toxicity. In addition, Zang et al. had shown an
anti-tumoural effect of Ad–TG-tk and Ad–CMV-tk in FRTL-
5, HEPG2, COS-1, MTC, HeLa and GH3 cells which were not
effective in the anaplastic form besides severe liver damage.
Barzon et al. have evaluated Re-tk-IL-2 in human ATC cell
line. This strategy had low efﬁciency in addition to the mild
side effects. Adenoviruses and other viruses have been engi-
neered for selective replication within neoplastic cells. It is al-
most impossible to deliver the virus to all the tumoural cells;
therefore, the uninfected tumoural cells will continue to
grow [7].
In this hypothesis, we focussed on the tumour suppressive
function of melanoma differentiation associated gene-7/inter-
leukin-24 (MDA-7/IL-24) in a xenograft mouse model for thy-
roid carcinoma. Based on the sequence homology, FISP is the
mouse orthologue of mda-7/IL-24 [8]. MDA-7, also known as
IL-24, is a member of the class II/IL-10 cytokine family [9,10]
and has been mapped to 1q32.2-q41 [11,12]. MDA-7 is ex-
pressed by the spleen, thymus and immune cells, including
TH2 cells, B cells, natural killer (NK) cells, dendritic cells,
monocytes and melanocytes [13–15]. Further, MDA-7 is
expressed in the villi, decidual tissue, villous column, tropho-
blasts, stroma and blood vessels [16]. The IL-20R1:IL-20R2
complex is a heterodimer receptor for IL-24. The latter also
signals through an IL-22R1/IL-20R2 heterodimer (type II
complex) [10,17–23]. Generally, epithelial cells are major
expression sites for IL-24 receptors [24]. A high level of IL-
20R1 messenger RNA (mRNA) expression was indicated in
the skin, testis, heart, placenta, salivary gland and prostate.
Mild expression was detected in brain, lung, stomach, pan-
creas, ovary, uterus, thyroid and adrenal glands. Scarce expres-
sion was observed in the kidney, liver, colon, muscle and smallintestine [25]. Mda-7 has at least two separate functions. It
mostly acts as a cytokine at low concentration. However, over-
expression of IL-24 at the supra-physiological level shows an
irreversible cancer cell growth inhibitory function and G2/M
cell cycle arrest, reversal of the malignant phenotype and ter-
minal differentiation, without negative effects on normal cells
[26,27]. When IL-24 as a cytokine binds to its receptor, Janus
activating kinase 1 (JAK1) is activated and causes the receptor
phosphorylation and creates binding sites for signal transduc-
ers and activators of transcription 1 (STAT1) and STAT3,
which are also phosphorylated by JAK1. The phosphorylated
STATs, in the nucleus, promote the transcription of cytokine-
regulated genes. This is the ﬁrst function of mda-7 [28,29].
However, it does not depend on this pathway to induce apop-
tosis [24]. Recombinant (r)IL-24 stimulates genes of the extrin-
sic and intrinsic apoptotic pathway such as Bax, Bak, Bid,
Casp8, cytochrome c oxidase subunit VIc (COX6C) and cyto-
chrome c oxidase subunit VIIb (COX7B) [30]. In fact, IL-24-
induced apoptosis is conducted through down-regulation of
Bcl-2, Bax and Akt [13]. However, Mda-7 induces the secretion
of interferon-beta (IFN-beta), which subsequently leads to
interferon regulatory factor (IRF-1) regulation and Fas/tu-
mour necrosis factor-related apoptosis-inducing ligand (Fas/
TRAIL) activation. Furthermore, MDA-7 has been implicated
in inducing cell death with the contribution of ceramide, a pro-
moter of apoptosis and a key mediator of the endoplasmic
reticulum (ER) stress pathway [31]. Mda-7/IL-24 binding to
BiP/GRP78 inactivates this ER-chaperone protein by in-
creased protein kinase RNA-activated (PKR)-like endoplas-
mic reticulum kinase (PERK) autophosphorylation and
increased phosphorylation of the downstream PERK target
(eukaryotic initiation factor 2, eIF2) [32,33] and therefore
could lead to a general suppression of protein expression,
particularly of anti-apoptotic proteins, such as Bcl2, Bcl-XL,
induced myeloid leukaemia cell differentiation protein
(MCL-1) and cellular FLICE-like inhibitory protein (c-FLIP)
[31] Mda-7/IL-24 induced ER stress and ceramide accumula-
tion, which triggered autophagy.
Producers of reactive oxygen species (ROS) enhance MDA-
7/IL-24 lethality. Overexpression of MDA-7/IL-24 in renal cell
carcinoma caused plasma membrane clustering of CD95 and
CD95 association with pro-caspase 8, which correlated with
enhanced cell killing [34]. IL-24 also has immune stimulatory
activity. It activates IL-6, tumour necrosis factor-a
(TNF-a) and interferon production and has been shown to
signiﬁcantly down-regulate transforming growth factor-b
(TGF-b) [35–37].The hypothesis
Thyroid cancer is the sixth most common type of cancer
among women and it is increasing more rapidly than any other
cancer. Therefore, development and evaluation of novel treat-
ment strategies, including immune gene therapy, are urgently
needed. In this proposal, we suggest inducing IL-24 gene
expression in the HTori human thyroid cell line and injection
of this cell line into a xenograft system. In the last years, IL-
24 has been introduced as a novel tumour suppressor gene
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is even applied in patients with some types of malignancies. We
expect that IL-24 can enhance malignant cell death through
apoptosis and other possible pathways in a thyroid mouse
model without any effect in normal cells.
Evaluation of hypothesis
 Cell culture: The human thyroid epithelial cell line (HTori-
3) is grown in phenol red-free RPMI 1640, supplemented
with 1% (v/v) antibiotics/antimycotics, 2 mmol/L of L-glu-
tamine and 10% (v/v) foetal calf serum (FCS) [38].
 Construction of recombinant adenovirus: The IL-24 expres-
sion cassette is cloned into the adenovirus shuttle plasmid
pCA13 to form pCA13–IL-24 and cut with BglII to clone
into ZD55 to form pZD55–IL-24. Replication-defective
adenovirus Ad–IL-24 is generated in HTori cells by homol-
ogous recombination. Recombinant adenovirus is ampliﬁed
in HTori cells and puriﬁed by caesium chloride-gradient
ultracentrifugation [34].
Brieﬂy, recombinant adenovirus plasmid pAd–mda-7 carry-
ing human mda-7/IL-24 complementary DNA (cDNA) is
transfected into the human thyroid epithelial cell line (HTor-
i-3) by Lipofectamine 2000 reagent, leading to the formation
of the recombinant adenovirus, Ad–IL-24. At the same time,
the recombinant adenovirus Ad-GFP carrying green ﬂuores-
cent protein (GFP) is constructed as a control.
 Tumour xenograft in nude mice: A total of 40 athymic mice
(AthymicNCr-nu/nu; 4 weeks old) are prepared. The ﬁrst
group (n= 10) contains control animals, which do not
receive any injection. The remaining mice are divided into
three categories of 10 animals each, including the following:
(a) Ten mice are selected for HTori cell-line inoculation. HTori
cells (5 · 106) in 200 ll of suspension mixture are injected
subcutaneously (s.c.) into the right ﬂank of athymic mice.
Tumours are measured weekly and the ‘end’ point was
reached when the tumours reached 3 cm in diameter [38].
(b) The second group received HTori cells and empty ade-
novirus vector.
(c) The next group includes mice that are injected with
HTori cells according to the above instruction. This
group received Ad–IL-24 (Fig. 1).
 RNA isolation and reverse transcriptase-polymerase chain
reaction (RT-PCR): RNA from cells is extracted using an
RNA extraction kit and cDNA synthesis and RT-PCR
are performed.
 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay: The cytotoxic activity of Ad–IL-24 is deter-
mined based on cytotoxicity to HTori cells, using the MTT
assay.
 Enzyme-linked Immunosorbent Assay (ELISA): ELISA is
performed to measure level of IL-24 in blood.
 Terminal deoxynucleotidyl transferase deoxy-uridinetri-
phosphate (dUTP) nick end labelling (TUNEL) test: This
test is used to assay DNA fragmentation, as a marker of
apoptosis [39,40]. Evaluating IFN-gamma, Granzyme B, TNF-alpha and IL-
24 through ELISA assay.
Discussion and conclusion
Given the lack of a promising cure for thyroid malignancy,
cytokine gene therapy for cancer has been recognised as an
efﬁcient and novel treatment with the minimum side effects
[5,6]. Among cytokines, mda-7/IL-24 as a new tumour sup-
pressor gene has been investigated in animal models and
in vitro studies [26,27]. Many studies show cytotoxic effects
of IL-24 in various types of cancer cell lines, including glioma,
ovarian, breast, lung, liver, pancreatic, gastric, colorectal, renal
and prostate cancer cells [41,42]. In addition, overexpression of
mda-7 in cervical cancer, ﬁbrosarcoma, melanoma, hepatoma
and osteosarcoma cell lines led to programmed cell death. Fur-
thermore, the anti-tumour activity of IL-24 has been estab-
lished in some tumour xenograft models and even in patients
with advanced solid cancers [13,14,28,43]. MDA-7 also inﬂu-
ences endothelial cells and has an anti-angiogenic effect within
the tumour vasculature [13,9]. A Phase I/II clinical trial in pa-
tients with advanced carcinomas involving intratumoural
administration of mda-7/IL-24 has documented that this gene
is safe and well tolerated by patients and a single virus injec-
tion elicits apoptosis in a majority of the tumours [44,45].
cDNA libraries produced from H0-1 cells treated with
IFN-beta + mezerein (MEZ) led to identiﬁcation of this gene
[46,47].
Our hypothesis suggested that Ad–IL-24 can inhibit the
growth and proliferation of human epithelial thyroid HTori
cells in tumour-bearing mice. IL-24 is a regulator of cell differ-
entiation, cell growth and apoptosis and a promising antican-
cer agent in many types of tumour cell lines without toxic
effects in ‘normal’ cell types [40,48]. This cytokine can induce
both intrinsic and extrinsic apoptosis pathways. In the extrin-
sic pathway, IL-24 efﬁciently could suppress tumours through
TNF-a and activation of the caspase 8–caspase 3 [48]; in the
intrinsic pathway, induction of caspase 9 and bax gene expres-
sion were observed [37]. In ovarian cancer, mda-7/IL24 was re-
ported to induce the extrinsic apoptosis pathway and also kill
multiple renal carcinoma cell lines, also via activation of the
CD95/FAS receptor [32]. IL-24-induced inhibition of cell pro-
liferation was associated with the transcriptional up-regulation
of the cell cycle inhibitors mediated by STAT3 activation
[49,50]. Another study demonstrated the potential anti-tumour
activity of IFN-a combined with IL-24 in hepatocellular carci-
noma (HCC) both in vitro and in vivo [51]. Interestingly, stud-
ies have shown that one mechanism of clinically effective IL-2
therapy may be the direct action of IL-2 on up-regulation of
the tumour suppressor IL-24 [52]. Mda-7/IL-24 also can en-
hance tumour sensitivity to radiation therapy [53,54]. Recent
studies have demonstrated that IL-24 can regulate ER stress
following the binding of the protein to BiP/GRP78. This bind-
ing eventually leads to the phosphorylation of eIF2 and there-
fore to a general suppression of anti-apoptotic proteins, such
as Bcl-XL, MCL-1 and c-FLIP [31]. Further in vivo data
showed that IL-24 suppressed tumour growth through
up-regulating the expression of bax and down-regulating the
Figure 1 IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma schematic design of hypothesis procedure. Function of
IL-24 in different cells.
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(VEGF) [28,29,49,55,56].
Moreover, IL-24 induces cancer cell-speciﬁc oxidative stress
by generation of ROS followed by mitochondrial dysfunction
uniquely in cancer cells [43]. Therefore, the canonical mecha-
nism by which diverse cytokines, including members of the
IL-10 gene family, are proposed to mediate bioactivity is by
binding to deﬁned cell surface receptors and activating JAK/
STAT signalling pathways. In the case of mda-7/IL-24,
JAK1/STAT3 activation is induced after binding of the
Mda-7/IL-24 protein to the IL-20R1/IL-20R2 and IL-22R1/
IL-20R2 receptors. Meanwhile, cell killing by mda-7/IL-24
did not require functional cell-surface receptors or STATactivation, and inhibition of tyrosine kinase activity or infec-
tion of cancer cells defective in speciﬁc components of the
JAK/STAT signalling pathway still elicited apoptosis [37,55].
However, Mda-7 expression is substantially reduced in malig-
nant breast tissue and low transcript levels are signiﬁcantly
associated with unfavourable pathological parameters.
Mda-7 probably offers utility as a prognostic marker in
thyroid carcinoma [13].
In conclusion, cytokine gene therapy demonstrates safety
and effectiveness in thyroid carcinoma. Specially, IL-24 could
act as an effective anticancer agent in this cancer via inducing
apoptosis, according to recent documents on many other types
of cancer.
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about the subject?
Thyroid cancer incidence is increasing
more rapidly than any other malignancy.
The expected annual number of newly
diagnosed thyroid cancer cases in the US
has reached 37,340. Despite current treat-
ments for thyroid cancer, other efﬁcient
approaches are necessary. It is veriﬁed that
IL-24 has tumour suppressor function
through inducing both intrinsic and extrin-
sic apoptosis pathways. Interestingly, simi-
lar effects are not apparent following
transduction into their non-malignant
counterparts. IL-24 can suppress cancer cell
growth, induce cancer cell apoptosis, inhibit
angiogenesis and enhance the anti-tumour
activity of radiotherapy, chemotherapy
and targeting gene-virotherapy.
Second Question: What does your proposed
theory add to the current knowledge avail-
able, and what beneﬁts does it have?
IL-24 could be considered a novel candi-
date in the gene therapy of thyroid cancer.
It could suppress the thyroid tumoural cell
growth and angiogenesis conspicuously
through up-regulating the expression of
pro-apoptotic proteins (bax and Bak) and
down-regulating the expression of bcl-2,
Bcl-xL and VEGF, promoting a shift from
survival to programmed cell death.
Third question: Among numerous available
studies, what special further study is proposed
for testing the idea?
To test this idea, initially epithelial thyroid
tumoural cells are induced in a mouse model
via an adenovirus vector. Then, the anti-
tumoural effect of IL-24 could be assessed
by methods of measurement of biomarkers
in blood levels.
In last phase, a clinical trial could be
performed.Acknowledgement
I am very thankful to my supervisor Dr Esmaeilzadeh who in-
spired and encouraged me for this hypothesis.References
[1] Al-Humadi H, Zarros A, Al-Saigh R, Liapi Ch. Genetic basis
and gene therapy trials for thyroid cancer. Cancer Genom
Proteom 2010;7:31–50.
[2] Thosani S, HuMI, Ahn P, Lamont JP. Thyroid and parathyroid
cancers. 14th ed. Cancer Management; 2011.
[3] Wartofsky L. Increasing world incidence of thyroid cancer:
increased detection or higher radiation exposure? Hormones
2010;9:103–8.
[4] Perez CA, Arango BA, Velez M, Raez LE, Santos ES. Emerging
role of multikinase inhibitors for refractory thyroid cancer. Biol
Targets Ther 2012;6:257–65.
[5] Li X, Abdel-Mageed AB, Kandil E. BRAF mutation in
papillary thyroid carcinoma. Int J Clin Exp Med 2012;5:310–5.
[6] Spitzweg C, Morris JC. Gene therapy for thyroid cancer: current
status and future prospects. Thyroid 2004;14:424–34.
[7] Xian J, Yang H, Lin Y, Liu S. Combination nonviral murine
interleukin 2 and interleukin 12 gene therapy and radiotherapy
for head and neck squamous cell carcinoma. Arch Otolaryngol
Head Neck Surg 2005;131(12):1079–85.
[8] Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD,
et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and
act on keratinocytes and are distinct from classical ILs. Exp
Dermatol 2006;15:991–1004.
[9] Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24
(MDA-7/MOB-5) signals through two heterodimeric receptors,
IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem
2002;277:7341–7 [Epub 2001 Nov 12].
[10] Imaeda H, Nishida A, Inatomi O, Fujiyama Y, Andoh A.
Expression of interleukin-24 and its receptor in human
pancreatic myoﬁbroblasts. Int J Mol Med 2011;28(6):993–9.
http://dx.doi.org/10.3892/ijmm.2011.793.
[11] Blumberg H, Conklin C, Xu WF, Grossmann A, Brender T,
Carollo S, et al. Interleukin 20: discovery, receptor
identiﬁcation, and role in epidermal function. Cell
2001;104:9–19.
[12] Witte E, Witte K, Warszawska K, Sabat R, Wolk K.
Interleukin-22: a cytokine produced by TNK and NKT cell
subsets, with importance in the innate immune defense and
tissue protection. Cytokine Growth 2010:365–9.
[13] Patani N, Douglas-Jones A, Mansel R, Jiang W, Mokbel K.
Tumour suppressor function of MDA-7/IL-24 in human breast
cancer. Cancer Cell Int 2010;10:29.
[14] Sainz-Perez A, Gary-Gouy H, Gaudin F, Maarof G, Marfaing-
Koka A, de Revel T, et al. IL-24 induces apoptosis of chronic
lymphocytic leukemia B cells engaged into the cell cycle through
dephosphorylation of STAT3 and stabilization of p53
expression. J Immunol 2008;181:6051–60.
[15] Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV,
Dent P, et al. Mda-7 (IL-24): signaling and Functional Roles.
BioTechniques 2002;33:S30–9.
[16] Cheng H, Zou L. IL-24 expression at maternal-fetal interface
and its roles in trophoblast invasion. J Huazhong Univ Sci
Technol Med Sci 2008;28(4):456–9. http://dx.doi.org/10.1007/
s11596-008-0418-9.
[17] He M, Liang P. IL-24 transgenic mice: in vivo evidence of
overlapping functions for IL-20, IL-22, and IL-24 in the
epidermis. J Immunol 2010;184:17931798. http://dx.doi.org/
10.4049/jimmunol.0901829.
[18] Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M,
Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia
via TNF and IL-20R2–dependent mechanisms with implications
for psoriasis pathogenesis. J Exp Med 2006;203:2577–87.
[19] Zhu H, Yang ZB. Expression pattern of mda-7/IL-24 receptors
in liver cancer cell lines. Hepatobiliary Pancreat Dis Int
2009;8:402–6.
12 M. Hajikhan Mirzaei, A. Esmaeilzadeh[20] Su L, Liao Q, Wu Y, Chen X. Kaposi’s sarcoma-associated
herpesvirus-encoded LANA down-regulates IL-22R1 expression
through a cis-acting element within the promoter region.
PLoS One 2011;6:e19106. http://dx.doi.org/10.1371/
journal.pone.0019106.
[21] Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR,
Walter MR. Structural basis for receptor sharing and activation
by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proc
Natl Acad Sci USA 2012;109:12704–9. http://dx.doi.org/
10.1073/pnas.1117551109 [[Epub 2012 Jul 16]].
[22] Coondoo A. Cytokines in dermatology – a basic overview.
Indian J Dermatol 2011;56:368–74.
[23] Kotenko SV. The family of IL-10-related cytokines and their
receptors: related, but to what extent? Cytokine Growth Factor
Rev 2002;13:223–40.
[24] Andoh A, Shioya M, Nishida A, Bamba S, Tsujikawa T, Kim-
Mitsuyama S, et al. Expression of IL-24, an activator of the
JAK1/STAT3/SOCS3 cascade, is enhanced in inﬂammatory
bowel disease. J Immunol 2009;183:687–95. http://dx.doi.org/
10.4049/jimmunol.0804169 [Epub 2009 Jun 17].
[25] Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV,
Anantha S, et al. Cutting Edge: IL-26 signals through a novel
receptor complex composed of IL-20 receptor 1 and IL-10
receptor 2. J Immunol 2004;172:2006–10.
[26] Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB,
Mhashilkar AM, et al. Mda-7/IL24 kills pancreatic cancer cells
by inhibition of the Wnt/PI3K signaling pathways: identiﬁcation
of IL-20 receptor-mediated bystander activity against pancreatic
cancer. Mol Ther 2005;11:724–33.
[27] Whitaker EL, Filippov VA, Filippova M, Guerrero-Juarez CF,
Duerksen-Hughes PJ. Splice variants of mda-7/IL-24
differentially affect survival and induce apoptosis in U2OS
cells: Functional characterization of mda-7/IL-24 splice
isoforms. Cytokine 2011;56:272–81. http://dx.doi.org/10.1016/
j.cyto.2011.07.020 [Epub 2011 Aug 16].
[28] Zhu Y, Du X, Chen H, Xie Y, Sheng W, Yang J. Effect of
adenovirus-mediated ING4 and IL-24 co-expression on
chemosensitivity to human lung adenocarcinoma in vitro and
in vivo. Sheng Wu Gong Cheng Xue Bao 2011;27:85–94.
[29] Tian H, Wang J, Zhang B, Di J, Chen F, Li H, et al. MDA-7/
IL-24 induces Bcl-2 denitrosylation and Ubiquitin-degradation
involved in cancer cell apoptosis. PLoS One 2012;7(5):e37200.
http://dx.doi.org/10.1371/journal.pone.0037200 [Epub 2012
May 21].
[30] Hadife N, Nemos C, Frippiat JP, Hamade´ T, Perrot A, Dalloul
A. Interleukin-24 mediates apoptosis in human B-cells through
early activation of cell cycle arrest followed by late induction of
the mitochondrial apoptosis pathway. Leuk Lymphoma 2012
[Epub ahead of print].
[31] Argiris K, Panethymitaki C, Tavassoli M. Naturally occurring,
tumor-speciﬁc, therapeutic proteins. Exp Biol Med (Maywood)
2011;236:524–36. http://dx.doi.org/10.1258/ebm.2011.011004.
[32] Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R,
Allegood J, et al. A serotype 5/3 Adenovirus expressing mda-7/
IL-24 infects renal carcinoma cells and promotes toxicity of
agents that increase Ros and Ceramide levels. Mol Pharmacol
2011;79:368–80. http://dx.doi.org/10.1124/mol.110.069484.
[33] Sauane M, Su ZZ, Dash R, Liu X, Norris JS, Sarkar D, et al.
Ceramide plays a prominent role in Mda-7/IL-24-induced
cancer-speciﬁc apoptosis. J Cell Physiol 2010;222:546–55.
[34] Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, et al.
Potent antitumor activity of oncolytic adenovirus expressing
mda-7/IL-24 for colorectal cancer. Hum Gene Ther
2005;16:845–58.
[35] Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm
EA. Soluble human MDA-7/IL-24: characterization of the
molecular form(s) inhibiting tumor growth and stimulating
monocytes. J Interferon Cytokine Res 2006;26(12):877–86.[36] Zhang BF, Liu JJ, Pei DS, Yang ZX, Di JH, Chen FF, et al.
Potent antitumor effect elicited by RGD-mda-7, an mda-7/IL-24
mutant, via targeting the integrin receptor of tumor cells. Cancer
Biother Radiopharm 2011;26(5):647–55. http://dx.doi.org/
10.1089/cbr.2011.0984 [Epub 2011 Sep 8].
[37] Fisher PB. Is mda-7/IL-24 a ‘‘Magic Bullet’’ for Cancer? Cancer
Res 2005;65:10128. http://dx.doi.org/10.1158/0008-5472.CAN-
05-3127.
[38] Kim DW, Zhao L, Hanover J, Willingham M, Cheng SY.
Thyroid hormone receptor b suppresses SV40-mediated
tumorigenesis via novel nongenomic actions. Am J Cancer Res
2012;2(5):606–19.
[39] Piri Z, Esmaeilzadeh AR, Hajikhanmirzaei M. Interleukin-25 as
a candidate gene in immunogene therapy of pancreatic cancer.
JMHI 2012;6(2):75–9.
[40] Mazaheri T, Esmaeilzadeh AR, H.KH Mirzaei M. Introducing
the immunomodulatory effects of mesenchymal stem cells in an
experimental model of Behc¸et’s disease. JMHI 2012;6(1):223–27.
[41] Whitaker EL, Filippov VA, Duerksen-Hughes PJ. Interleukin
24: mechanisms and therapeutic potential of an anti-cancer gene.
Cytokine Growth Factor Rev 2012;23:323–31. http://dx.doi.org/
10.1016/j.cytogfr.2012.08.004 [Epub 2012 Sep 14].
[42] Pei DS, Yang ZX, Zhang BF, Yin XX, Li LT, Li HZ, et al.
Enhanced apoptosis-inducing function of MDA-7/IL-24 RGD
mutant via the increased adhesion to tumor cells. J Interferon
Cytokine Res 2012;32(2):66–73. http://dx.doi.org/10.1089/
jir.2011.0040 [Epub 2012 Jan 16].
[43] Sahoo A, Jung YM, Kwon HK, Yi HJ, Lee S, Chang S, et al. A
novel splicing variant of mouse interleukin (IL)-24 antagonizes
IL-24-induced apoptosis. J Biol Chem 2008;283:28860–72.
http://dx.doi.org/10.1074/jbc.M802510200 [Epub 2008 Aug 15].
[44] Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA,
et al. Enhanced delivery of mda-7/IL-24 using a serotype
chimeric adenovirus (Ad.5/3) in combination with the
Apogossypol derivative BI-97C1 (Sabutoclax) improves
therapeutic efﬁcacy in low CAR colorectal cancer cells. J Cell
Physiol 2012;227(5):2145–53. http://dx.doi.org/10.1002/
jcp.22947.
[45] Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm
EA, Rosenfeld MR, et al. Mda-7/IL-24, a novel cancer selective
apoptosis inducing cytokine gene: from the laboratory into the
clinic. Cancer Biol Ther 2003;2:S23–37.
[46] Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction
hybridization identiﬁes a novel melanoma differentiation
associated gene, mda-7, modulated during human melanoma
differentiation, growth and progression. Oncogene
1995;11(12):2477–86.
[47] Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB.
The melanoma differentiation associated gene mda-7 suppresses
cancer cell growth. Proc Natl Acad Sci USA
1996;93(17):9160–5.
[48] Bosanquet DC, Harding KG, Ruge F, Sanders AJ, Jiang WG.
Expression of IL-24 and IL-24 receptors in human wound
tissues and the biological implications of IL-24 on keratinocytes.
Wound Repair Regen 2012;20:896–903. http://dx.doi.org/
10.1111/j.1524-475X.2012.00840.x.
[49] Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K,
Inokuchi K, et al. AAV8 vector expressing IL24 efﬁciently
suppresses tumor growth mediated by speciﬁc mechanisms in
MLL/AF4-positive ALL model mice. Blood 2012;119:64–71.
http://dx.doi.org/10.1182/blood-2011-05-354050.
[50] Xuan W, Li YJ, Liu G, Ben-David Y, Archer MC. Interleukin-
24 induces expression of b4 integrin but suppresses anchorage-
independent growth of rat mammary tumor cells by a
mechanism that is independent of b4. Mol Cancer Res
2009;7:433–42.
[51] Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ,
et al. Interferon-a enhances antitumor activities of oncolytic
Overexpression of MDA-7/IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma 13adenovirus-mediated IL-24 expression in hepatocellular
carcinoma. Mol Cancer 2012;11(17):31.
[52] Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA. IL-2
regulates the expression of the tumor suppressor IL-24 in
melanoma cells. Melanoma Res 2012 Feb;22(1):19–29. http://
dx.doi.org/10.1097/CMR.0b013e32834d2506.
[53] Tirodkar TS, Voelkel-Johnson C. Sphingolipids in apoptosis.
Exp Oncol 2012;34(3):231–42.
[54] Sahoo A, Im SH. Molecular mechanisms governing IL-24 gene
expression. Immune Network 2012;12(1):1–7.[55] Dash R, Richards JE, Su ZZ, Bhutia SK, Azab B, Rahmani M,
et al. Mechanism by which Mcl-1 regulates cancer-speciﬁc
apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine.
Cancer Res 2010;70:5034–45.
[56] Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK,
et al. MDA-7/IL-24 as a cancer therapeutic: from bench to
bedside. Anticancer Drugs 2010;21(8):725–31. http://dx.doi.org/
10.1097/CAD.0b013e32833cfbe1.
